Pulmonary tuberculosis - New and future therapeutic aspects

J. H. Grosset, C. Truffot-Pernot, H. Lecoeur

Research output: Contribution to journalArticle

Abstract

The duration of treatment of pulmonary tuberculosis caused by non-resistant tubercle bacilli, was shortened by combination treatment with pyrazinamide. The classical treatment regimen lasting 9 months and comprising the daily administration of isoniazid 5 mg/kg, rifampicin 10 mg/kg, and ethambutol 20 mg/kg over a period of 2 months, followed by isoniazid and rifampicin over the next 7 months has now been replaced by a shortened regimen that lasts for 6 months. This latter comprises the daily administration of the above-mentioned antituberculous drugs, with the addition of pyrazinamide 30 mg/kg, and isoniazid and rifampicin over the following 4 months. With this 'short regimen', as in the case of the classical therapeutic regimen, the relapse rate is of the order of 1%, even in cases of initial resistance to isoniazid. In the event of acquired resistance to isoniazid and rifampicin, two therapeutic strategies are possible: 1. discontinuation of treatment to await the results of resistance testing; 2. administration of a number of antibiotics that are continued until the results of testing are known. The new quinolones (perfloxacin, ofloxacin) and the derivatives of rifamycin SV (LM 427 or ansamycin) open up new therapeutic perspectives, not merely for the cases of multi-resistant tuberculosis, but also for mycobacterioses. Patients with negative tuberculosis culture profit from a treatment regimen of even shorter duration (2-3 months), comprising a combination of isoniazid, rifampicin and pyrazinamide.

Original languageEnglish (US)
Pages (from-to)206-210
Number of pages5
JournalPraxis und Klinik der Pneumologie
Volume42
Issue numberSPEC. ISS. 1
StatePublished - 1988
Externally publishedYes

Fingerprint

Pulmonary Tuberculosis
Isoniazid
Rifampin
Pyrazinamide
Rifabutin
Therapeutics
Tuberculosis
Ethambutol
Ofloxacin
Quinolones
Bacillus
Anti-Bacterial Agents
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Grosset, J. H., Truffot-Pernot, C., & Lecoeur, H. (1988). Pulmonary tuberculosis - New and future therapeutic aspects. Praxis und Klinik der Pneumologie, 42(SPEC. ISS. 1), 206-210.

Pulmonary tuberculosis - New and future therapeutic aspects. / Grosset, J. H.; Truffot-Pernot, C.; Lecoeur, H.

In: Praxis und Klinik der Pneumologie, Vol. 42, No. SPEC. ISS. 1, 1988, p. 206-210.

Research output: Contribution to journalArticle

Grosset, JH, Truffot-Pernot, C & Lecoeur, H 1988, 'Pulmonary tuberculosis - New and future therapeutic aspects', Praxis und Klinik der Pneumologie, vol. 42, no. SPEC. ISS. 1, pp. 206-210.
Grosset JH, Truffot-Pernot C, Lecoeur H. Pulmonary tuberculosis - New and future therapeutic aspects. Praxis und Klinik der Pneumologie. 1988;42(SPEC. ISS. 1):206-210.
Grosset, J. H. ; Truffot-Pernot, C. ; Lecoeur, H. / Pulmonary tuberculosis - New and future therapeutic aspects. In: Praxis und Klinik der Pneumologie. 1988 ; Vol. 42, No. SPEC. ISS. 1. pp. 206-210.
@article{b4641a7d36ef483b830661fe7000d9d7,
title = "Pulmonary tuberculosis - New and future therapeutic aspects",
abstract = "The duration of treatment of pulmonary tuberculosis caused by non-resistant tubercle bacilli, was shortened by combination treatment with pyrazinamide. The classical treatment regimen lasting 9 months and comprising the daily administration of isoniazid 5 mg/kg, rifampicin 10 mg/kg, and ethambutol 20 mg/kg over a period of 2 months, followed by isoniazid and rifampicin over the next 7 months has now been replaced by a shortened regimen that lasts for 6 months. This latter comprises the daily administration of the above-mentioned antituberculous drugs, with the addition of pyrazinamide 30 mg/kg, and isoniazid and rifampicin over the following 4 months. With this 'short regimen', as in the case of the classical therapeutic regimen, the relapse rate is of the order of 1{\%}, even in cases of initial resistance to isoniazid. In the event of acquired resistance to isoniazid and rifampicin, two therapeutic strategies are possible: 1. discontinuation of treatment to await the results of resistance testing; 2. administration of a number of antibiotics that are continued until the results of testing are known. The new quinolones (perfloxacin, ofloxacin) and the derivatives of rifamycin SV (LM 427 or ansamycin) open up new therapeutic perspectives, not merely for the cases of multi-resistant tuberculosis, but also for mycobacterioses. Patients with negative tuberculosis culture profit from a treatment regimen of even shorter duration (2-3 months), comprising a combination of isoniazid, rifampicin and pyrazinamide.",
author = "Grosset, {J. H.} and C. Truffot-Pernot and H. Lecoeur",
year = "1988",
language = "English (US)",
volume = "42",
pages = "206--210",
journal = "Pneumologie",
issn = "0934-8387",
publisher = "Georg Thieme Verlag",
number = "SPEC. ISS. 1",

}

TY - JOUR

T1 - Pulmonary tuberculosis - New and future therapeutic aspects

AU - Grosset, J. H.

AU - Truffot-Pernot, C.

AU - Lecoeur, H.

PY - 1988

Y1 - 1988

N2 - The duration of treatment of pulmonary tuberculosis caused by non-resistant tubercle bacilli, was shortened by combination treatment with pyrazinamide. The classical treatment regimen lasting 9 months and comprising the daily administration of isoniazid 5 mg/kg, rifampicin 10 mg/kg, and ethambutol 20 mg/kg over a period of 2 months, followed by isoniazid and rifampicin over the next 7 months has now been replaced by a shortened regimen that lasts for 6 months. This latter comprises the daily administration of the above-mentioned antituberculous drugs, with the addition of pyrazinamide 30 mg/kg, and isoniazid and rifampicin over the following 4 months. With this 'short regimen', as in the case of the classical therapeutic regimen, the relapse rate is of the order of 1%, even in cases of initial resistance to isoniazid. In the event of acquired resistance to isoniazid and rifampicin, two therapeutic strategies are possible: 1. discontinuation of treatment to await the results of resistance testing; 2. administration of a number of antibiotics that are continued until the results of testing are known. The new quinolones (perfloxacin, ofloxacin) and the derivatives of rifamycin SV (LM 427 or ansamycin) open up new therapeutic perspectives, not merely for the cases of multi-resistant tuberculosis, but also for mycobacterioses. Patients with negative tuberculosis culture profit from a treatment regimen of even shorter duration (2-3 months), comprising a combination of isoniazid, rifampicin and pyrazinamide.

AB - The duration of treatment of pulmonary tuberculosis caused by non-resistant tubercle bacilli, was shortened by combination treatment with pyrazinamide. The classical treatment regimen lasting 9 months and comprising the daily administration of isoniazid 5 mg/kg, rifampicin 10 mg/kg, and ethambutol 20 mg/kg over a period of 2 months, followed by isoniazid and rifampicin over the next 7 months has now been replaced by a shortened regimen that lasts for 6 months. This latter comprises the daily administration of the above-mentioned antituberculous drugs, with the addition of pyrazinamide 30 mg/kg, and isoniazid and rifampicin over the following 4 months. With this 'short regimen', as in the case of the classical therapeutic regimen, the relapse rate is of the order of 1%, even in cases of initial resistance to isoniazid. In the event of acquired resistance to isoniazid and rifampicin, two therapeutic strategies are possible: 1. discontinuation of treatment to await the results of resistance testing; 2. administration of a number of antibiotics that are continued until the results of testing are known. The new quinolones (perfloxacin, ofloxacin) and the derivatives of rifamycin SV (LM 427 or ansamycin) open up new therapeutic perspectives, not merely for the cases of multi-resistant tuberculosis, but also for mycobacterioses. Patients with negative tuberculosis culture profit from a treatment regimen of even shorter duration (2-3 months), comprising a combination of isoniazid, rifampicin and pyrazinamide.

UR - http://www.scopus.com/inward/record.url?scp=0024025718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024025718&partnerID=8YFLogxK

M3 - Article

C2 - 3174565

AN - SCOPUS:0024025718

VL - 42

SP - 206

EP - 210

JO - Pneumologie

JF - Pneumologie

SN - 0934-8387

IS - SPEC. ISS. 1

ER -